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protein restriction slows the progression of kidney disease delay-
ing the dialysis treatment. The cost of treatment of end-stage
renal disease is high and increases with age. Therefore, delaying
the start of renal replacement therapy with hemodialysis and
improving the patient’s quality of life are two primary goals
justifying the use of protein-restricted diets. The aim of the study
was to evaluate the economic impact of a low-protein diet (0.6 gr
proteins/kg, body weight/day) with the intent of delay the hae-
modialysis treatment in patients with advanced chronic-renal-
failure. METHODS: The study was a naturalistic, longitudinal
retrospective Cost of Treatment study. Patients were enrolled
during the 2005 and followed up until 2007 or the beginning of
haemodialysis treatment. Direct health care resources attribut-
able to disease management (drugs, ambulatory care, day case
treatments, hospitalizations, specialist visits, diagnostics and
laboratory exams) were quantiﬁed using National Health Service
(NHS) tariffs expressed in Euro 2008. NHS perspective was
adopted. Health-related quality of life information were also
collected using SF-36 questionnaire at the enrolment and at the
end of the observation period. RESULTS: We enrolled 30
patients (males 60%, mean age of 56.5  13.9 y.o.) from the
Nephrology Department of the University “Federico II” of
Naples, with a mean follow-up of 12.7  7.5 months. The
average monthly cost of care was €1075.6  925.2 per patient,
mainly because of hospitalization which represented the 45.0%
of the expenses. SF-36 results showed a quality of life stable
during the observation period and quite similar to the general
population. CONCLUSIONS: This is the ﬁrst study evaluating
the economic impact of law-protein diet in patients with CRF in
Italy. The protein-restricted diets helps to delay initiation of
hemodialysis sessions, which substantially increase treatment
costs and negatively impacts quality of life.
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OBJECTIVES: The aim of this study was to assess the cost-
effectiveness of solifenacin (5 mg/10 mg) relative to tolterodine
ER 4 mg in the treatment of patients with overactive bladder
(OAB), from the perspective of the UK (NHS) health care system.
METHODS: This was a cost-utility analysis based on a one-year
decision-tree model. A systematic review and meta-analysis of
efﬁcacy data was performed to obtain estimates for clinical effec-
tiveness. The beneﬁts of treatment were measured according to
resolution of OAB symptoms and subsequent improvement in
health-related quality of life (HRQoL). Treatment success was
deﬁned separately for urgency, frequency and incontinence. Deﬁ-
nitions of treatment success were no urge episodes, eight or fewer
micturitions and no incontinence episodes per 24 hours respec-
tively. Incremental cost-effectiveness ratios (ICERs) were esti-
mated separately for each symptom. HRQoL values were taken
from published sources. Treatment persistence data and data for
the proportion of solifenacin patients receiving the higher dose,
10-mg formulation were obtained from the DIN-LINK database.
The analysis was undertaken from the perspective of the UK
NHS and included costs directly associated with the treatment of
OAB, i.e. cost of antimuscarinics, GP consultations and consul-
tations in an outpatient clinic; cost data was taken from NHS
published sources (at 2007/2008 prices). Resource utilisation
was based on expert opinion. RESULTS: ICERs fell below
£15,000/QALY in all analyses: £6,406/QALY, £9,065/QALY and
£14,374/QALY for urgency, frequency and incontinence out-
comes, respectively. ICERs remained below the threshold of
£30,000/QALY throughout univariate sensitivity analyses.
CONCLUSIONS: Treatment with solifenacin 5 mg/10 mg is
likely to be a cost-effective treatment strategy relative to toltero-
dine ER 4 mg in the UK healthc are setting.
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OBJECTIVES: The aim of this study was to assess the cost-
effectiveness of solifenacin (5 mg/10 mg) relative to fesoterodine
(4 mg/8 mg) for OAB, from the perspective of the UK (NHS)
health care system. METHODS: A cost-utility analysis was
undertaken using a one-year decision-tree model. Estimates for
clinical effectiveness were obtained from a systematic review
and meta-analysis. Treatment success was deﬁned separately for
urgency, frequency and incontinence. Deﬁnitions of treatment
success were no urgency episodes, eight or fewer micturitions and
no incontinence episodes per 24 hours. Incremental cost-
effectiveness ratios (ICERs) were estimated separately for each
symptom. Treatment persistence rates for solifenacin and the
percentage of patients requiring the higher-dose formulation of
solifenacin were taken from the DIN-LINK database. In the
absence of these data for fesoterodine, in the base case analysis
treatment persistence and the percentage of patients requiring
the higher dose formulation of fesoterodine were assumed to be
equal to that for solifenacin. Utility values for the calculation of
Quality Adjusted Life Years (QALYs) were taken from published
sources. The analysis included costs directly associated with OAB
treatment, i.e. antimuscarinic therapy, GP consultations and out-
patient contacts; cost data were taken from NHS published
sources (2007/2008 prices). Resource utilisation was based on
expert opinion. RESULTS: In the base-case analysis, solifenacin
resulted in a cost-effective treatment strategy compared with
fesoterodine for urgency and frequency outcomes being both
more effective and less costly. Fesoterodine was more effective
but more expensive than solifenacin for incontinence, with an
ICER of £84,686/QALY. CONCLUSIONS: This analysis sug-
gests that fesoterodine does not provide a cost-effective treatment
option relative to solifenacin at a cost-effectiveness threshold of
£30,000/QALY for the resolution of urgency, frequency and
incontinence in patients treated for OAB.
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OBJECTIVES: At present, expanded criteria donors suppose up
to 40–50% of the renal transplant. The aim was to evaluate
cost-utility difference between standard criteria donors (SCD)
versus expanded criteria donors (ECD) at the ﬁrst year of kidney
transplant. METHODS: Patients were collected in the waiting-
list for renal transplant in our region from January 1, 2003 to
December 31, 2005. Clinical and demographic variables, trans-
plant costs and EQ-5D tariff, as a generic perceived state of
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health (PSH) proﬁle, were analyzed. RESULTS: A total of 131
patients were included in the waiting-list and 80% received a
kidney transplant, 41% were ECD. Sixty percent were men. The
age difference between ECD, SCD and not transplanted was
signiﬁcant (p = 0.000). The mean time in waiting-list (15 months)
and cold ischemia time (14 hours) were the same for both groups.
There were no differences in clinical variables. The PSH improve-
ment in ECD at year was signiﬁcant (p = 0.022), whereas for the
SCD not. There were differences in incomes (p = 0.041) between
groups. The survival at ﬁrst year was 100% for SCD and 97.7%
for ECD. At year, mean cost for SCD transplant was €54,343/year
versus €59.13€/year for ECD (no signiﬁcant). The difference in
QALYs between transplanted ones and not-transplanted was
signiﬁcant (p = 0.019). The utility was: 0.8096 QALYs for SCD,
0.7786 for ECD and 0.6838 for not transplanted. Cost-utility
analysis showed that one QALY in SCD cost €67.27€, versus
€79.95€/QALY of ECD and €80.43€/QALY of not transplanted in
waiting list. CONCLUSIONS: There were no clinical differences
and not in PSH at the ﬁrst transplant year between SCD and ECD,
but there were in age and what it bears. The differences in terms of
cost-utility, in the ﬁrst year, between ECD and not transplanted
were small. However, the differences could be important in long
term, because after the ﬁrst year the costs have an important
decrease. Therefore, it seems that ECD transplant have a good
results in health and costs.
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OBJECTIVES: To assess the cost and the resource use related to
anaemia management with Aranesp®, Eprex® and Neorecor-
mon(r) in patients with chronic renal failure treated with hae-
modialysis in Belgium; and to assess the effect of anaemia
management on haemoglobin (Hb) levels. METHODS: Data on
anaemia management and resource utilization were collected
using a retrospective chart review conducted in 11 haemodialysis
centres distributed across Belgium. From each centre between 30
and 40 patients were randomly selected. Data on drug use,
transfusion, consultations, hospitalizations, diagnostic tests and
Hb level were collected over a 1-year study period (1 December
2005 until 30 November 2006). The costs were calculated by
multiplying each item of resource use with its unit cost (in 2007;
in €) from the Belgian health care payer’s perspective (RIZIV/
INAMI). RESULTS: A total of 335 patients were included of
which 105, 132 and 98 were treated with Aranesp®, Eprex® and
Neorecormon(r), respectively. There were no demographic dif-
ferences between the treatment arms. There were no statistically
signiﬁcant differences between the 3 ESAs in the total annual
anaemia management cost in haemodialysis treated chronic renal
failure patients despite differences in drug list prices between the
3 ESAs. The cost ranged from €8203 to €9281. There were no
signiﬁcant differences in the average weekly dose of ESA between
the 3 drugs. Independent of the iron status of the patient, or
when stratiﬁed by CRP level, the percentage of patients reaching
a Hb level  11 g/dl was similar in the 3 treatment arms and
ranged from 76% to 81%. CONCLUSIONS: In patients with
chronic renal failure, treated with haemodialysis, there were no
signiﬁcant differences between the 3 available ESAs in medical
resource use, average dose of ESA needed, annual anaemia man-
agement costs from the perspective of the Belgian public health
care payer and in Hb control.
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OBJECTIVES: Due to their duration of action, current erythro-
poietin stimulating agents (ESA) require frequent administrations
(up to 3 injections per week). The objective of this study was a)
to estimate the potential time savings resulting from a switch to
a new once a month CERA (continuous erythropoietin receptor
activator), and b) to determine its beneﬁts in quality of care and
procedural improvements. METHODS: The different stages in
the global ESA Hospital Process (from ordering to invoicing)
were identiﬁed. A time and motion method was used for each
stage to determine the time spent managing ESA in eight dialysis
centres with different proﬁles. Simulations were performed to
assess the time savings according to various levels of the new
product’s penetration rates. Qualitative interviews with the
medical and administrative staff involved in the ESA manage-
ment were carried out to assess the expected beneﬁts of switching
to monthly injections. Intermediary and ﬁnal results were vali-
dated by a Scientiﬁc Committee. RESULTS: Current ESA man-
agement requires between 6 h 12 min and 20 h 36 min per
patient per year. The estimated total time saved by switching
to monthly injections ranged from 5 h 13 min to 17 h 29 min per
patient per year. Pharmacists and nurses are the two staff catego-
ries most affected by the time savings, which are respectively
from 28 min to 13 h and from 51 min to 3 h 32 m per patient
per year. Qualitative interviews supported these results and also
highlighted a potential time savings for administrative staff.
CONCLUSIONS: Administration of a monthly CERA injection
could reduce total time spent on ESA management by up to 85%
(for a total conversion). Time saved would allow the staff
involved to improve both their organisation and procedures
(stock management, outdated products, etc.) and their quality of
care (optimisation for Continuing Professional Development
indicators: patient close monitoring, compliance, etc.).
URINARY/KIDNEY DISORDERS—
Patient-Reported Outcomes Studies
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OBJECTIVES: Many trials do not measure Quality Adjusted Life
Years (QALYs). Therefore decision analysts wishing to extrapo-
late trial results for policy makers often map condition speciﬁc
outcomes to preference scores. We estimated the relationship
between changes in preference scores and commonly reported
condition speciﬁc outcomes in patients with neurogenic urinary
incontinence (UI). METHODS: In 59 patients recruited to a
neurogenic UI randomised controlled trial, clinical outcomes (UI
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